These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

83 related articles for article (PubMed ID: 10344069)

  • 1. Efavirenz in the management of HIV infection.
    Gazzard BG
    Int J Clin Pract; 1999; 53(1):60-4. PubMed ID: 10344069
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. Study 006 Team.
    Staszewski S; Morales-Ramirez J; Tashima KT; Rachlis A; Skiest D; Stanford J; Stryker R; Johnson P; Labriola DF; Farina D; Manion DJ; Ruiz NM
    N Engl J Med; 1999 Dec; 341(25):1865-73. PubMed ID: 10601505
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Review of NNRTIs: 'today and tomorrow'.
    Katlama C
    Int J Clin Pract Suppl; 1999 Jun; 103():16-20. PubMed ID: 10622038
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Resistance profile and cross-resistance of HIV-1 among patients failing a non-nucleoside reverse transcriptase inhibitor-containing regimen.
    Delaugerre C; Rohban R; Simon A; Mouroux M; Tricot C; Agher R; Huraux JM; Katlama C; Calvez V
    J Med Virol; 2001 Nov; 65(3):445-8. PubMed ID: 11596076
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HIV-1 reverse transcriptase and protease resistance mutations selected during 16-72 weeks of therapy in isolates from antiretroviral therapy-experienced patients receiving abacavir/efavirenz/amprenavir in the CNA2007 study.
    Ait-Khaled M; Rakik A; Griffin P; Stone C; Richards N; Thomas D; Falloon J; Tisdale M;
    Antivir Ther; 2003 Apr; 8(2):111-20. PubMed ID: 12741623
    [TBL] [Abstract][Full Text] [Related]  

  • 6. First once-daily drug simplifies dosing, offers new options in HIV-1 treatment.
    AIDS Alert; 1998 Nov; 13(11):121-4. PubMed ID: 11365967
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV.
    Gallant JE; DeJesus E; Arribas JR; Pozniak AL; Gazzard B; Campo RE; Lu B; McColl D; Chuck S; Enejosa J; Toole JJ; Cheng AK;
    N Engl J Med; 2006 Jan; 354(3):251-60. PubMed ID: 16421366
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efavirenz: enhancing the gold standard.
    Arribas JR
    Int J STD AIDS; 2003 Oct; 14 Suppl 1():6-14. PubMed ID: 14617398
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cerebrospinal fluid human immunodeficiency virus type 1 (HIV-1) suppression and efavirenz drug concentrations in HIV-1-infected patients receiving combination therapy.
    Tashima KT; Caliendo AM; Ahmad M; Gormley JM; Fiske WD; Brennan JM; Flanigan TP
    J Infect Dis; 1999 Sep; 180(3):862-4. PubMed ID: 10438381
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical history of efavirenz.
    Ruiz N
    Int J Clin Pract Suppl; 1999 Jun; 103():3-7. PubMed ID: 10622035
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efavirenz: new preparation. An alternative to HIV protease inhibitors.
    Prescrire Int; 2000 Apr; 9(46):46-9. PubMed ID: 11503786
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Indinavir/ritonavir 800/100 mg bid and efavirenz 600 mg qd in patients failing treatment with combination nucleoside reverse transcriptase inhibitors: 96-week outcomes of HIV-NAT 009.
    Boyd MA; Siangphoe U; Ruxrungtham K; Duncombe CJ; Stek M; Lange JM; Cooper DA; Phanuphak P
    HIV Med; 2005 Nov; 6(6):410-20. PubMed ID: 16268823
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative biological and clinical outcomes after a switch from a virologically unsuccessful first protease inhibitor-containing antiretroviral combination to a 3-drug regimen containing efavirenz, nevirapine, or abacavir.
    Abgrall S; Yeni PG; Bouchaud O; Costagliola D;
    Clin Infect Dis; 2007 Jan; 44(1):120-7. PubMed ID: 17143827
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Abacavir versus zidovudine combined with lamivudine and efavirenz, for the treatment of antiretroviral-naive HIV-infected adults.
    DeJesus E; Herrera G; Teofilo E; Gerstoft J; Buendia CB; Brand JD; Brothers CH; Hernandez J; Castillo SA; Bonny T; Lanier ER; Scott TR;
    Clin Infect Dis; 2004 Oct; 39(7):1038-46. PubMed ID: 15472858
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An open-label, randomized comparative pilot study of a single-class quadruple therapy regimen versus a 2-class triple therapy regimen for individuals initiating antiretroviral therapy.
    Moyle G; Higgs C; Teague A; Mandalia S; Nelson M; Johnson M; Fisher M; Gazzard B
    Antivir Ther; 2006; 11(1):73-8. PubMed ID: 16518962
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and tolerability of long-term efavirenz plus nucleoside reverse transcriptase inhibitors for HIV-1 infection.
    Tashima K; Staszewski S; Nelson M; Rachlis A; Skiest D; Stryker R; Bessen L; Overfield S; Ruiz N; Wirtz V
    AIDS; 2008 Jan; 22(2):275-9. PubMed ID: 18097230
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efavirenz (Sustiva) may equal or exceed protease inhibitor in initial antiretroviral combination.
    James JS
    AIDS Treat News; 1998 Jul; (No 299):1-3. PubMed ID: 11365599
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Therapy with efavirenz plus indinavir in patients with extensive prior nucleoside reverse-transcriptase inhibitor experience: a randomized, double-blind, placebo-controlled trial.
    Haas DW; Fessel WJ; Delapenha RA; Kessler H; Seekins D; Kaplan M; Ruiz NM; Ploughman LM; Labriola DF; Manion DJ
    J Infect Dis; 2001 Feb; 183(3):392-400. PubMed ID: 11133370
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [The use of the non-nucleoside reverse transcriptase inhibitors nevirapine and efavirenz in the treatment of patients with a chronic HIV-I infection].
    van Leth F; Lange JM
    Ned Tijdschr Geneeskd; 2006 Aug; 150(31):1719-22. PubMed ID: 16924943
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A new HAART on the horizon says the proof is in the potency.
    AIDS Alert; 1999 Apr; 14(4):37-9. PubMed ID: 11366218
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.